Abstract
Normal hematopoiesis is maintained by dynamic interactions between hematopoietic cells and the bone marrow microenvironment. In hematological malignancies, there are reciprocal interactions between leukemic cells and cells of the bone marrow microenvironment such as stroma, osteoblasts and endothelium. In this review, we will discuss the influence of the microenvironment on the evolution of the leukemic phenotype. We propose that specific niches within the bone marrow microenvironment may provide a sanctuary for subpopulations of leukemic cells to evade chemotherapyinduced death and allow acquisition of a drug-resistant phenotype. We will also discuss recent studies that suggest novel therapeutic interventions targeting the microenvironment/leukemia interaction. Focus on this stroma-leukemia crosstalk may result in the development of strategies that alleviate the acquisition of a chemoresistant phenotype and enhance the efficacy of therapies in hematological malignancies.
Keywords: Leukemia, microenvironment, chemoresistance, angiogenesis
Current Drug Targets
Title: Targeting the Leukemia Microenvironment
Volume: 8 Issue: 6
Author(s): Marina Konopleva and Michael Andreeff
Affiliation:
Keywords: Leukemia, microenvironment, chemoresistance, angiogenesis
Abstract: Normal hematopoiesis is maintained by dynamic interactions between hematopoietic cells and the bone marrow microenvironment. In hematological malignancies, there are reciprocal interactions between leukemic cells and cells of the bone marrow microenvironment such as stroma, osteoblasts and endothelium. In this review, we will discuss the influence of the microenvironment on the evolution of the leukemic phenotype. We propose that specific niches within the bone marrow microenvironment may provide a sanctuary for subpopulations of leukemic cells to evade chemotherapyinduced death and allow acquisition of a drug-resistant phenotype. We will also discuss recent studies that suggest novel therapeutic interventions targeting the microenvironment/leukemia interaction. Focus on this stroma-leukemia crosstalk may result in the development of strategies that alleviate the acquisition of a chemoresistant phenotype and enhance the efficacy of therapies in hematological malignancies.
Export Options
About this article
Cite this article as:
Konopleva Marina and Andreeff Michael, Targeting the Leukemia Microenvironment, Current Drug Targets 2007; 8 (6) . https://dx.doi.org/10.2174/138945007780830827
DOI https://dx.doi.org/10.2174/138945007780830827 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Rationale of Targeting Neutrophils with Dapsone during Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Towards Cure of CML: Why We Need to Know More About CML Stem Cells?
Current Stem Cell Research & Therapy Targeted Strategies in the Treatment of Primary Gastric Lymphomas: From Rituximab to Recent Insights into Potential New Drugs
Current Medicinal Chemistry To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets The Role of B Cell Receptor Stimulation in CLL Pathogenesis
Current Pharmaceutical Design Potential Therapeutic Applications of miRNA-Based Technology in Hematological Malignancies
Current Pharmaceutical Design Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Procarbazine – A Traditional Drug in the Treatment of Malignant Gliomas
Current Medicinal Chemistry Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology Current Status and Future of Antifungal Therapy for Systemic Mycoses
Recent Patents on Anti-Infective Drug Discovery An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
Current Cancer Drug Targets Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents
Recent Patents on Anti-Cancer Drug Discovery Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Acyclonucleosides, Modified Seco-Nucleosides, and Salicyl- or Catechol- Derived Acyclic 5-Fluorouracil O,N-Acetals: Antiproliferative Activities, Cellular Differentiation and Apoptosis
Current Medicinal Chemistry The Role of Bevacizumab in Advanced Epithelial Ovarian Cancer
Current Pharmaceutical Design DNA Polymerases as Targets of Anticancer Nucleosides
Current Drug Targets Adverse Effects of Tacrolimus in Renal Transplant Patients from Living Donors
Current Drug Safety Combination Treatment of p53-Null HL-60 cells with Histone Deacetylase Inhibitors and Chlorambucil Augments Apoptosis and Increases BCL6 and p21 Gene Expression
Current Molecular Pharmacology Sphingolipid Metabolism and Leukemia: A Potential for Novel Therapeutic Approaches
Anti-Cancer Agents in Medicinal Chemistry